Summit Trail Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.11M Buy
43,831
+7,917
+22% +$1.11M 0.09% 127
2025
Q4
$4.41M Sell
35,914
-6,159
-15% -$748K 0.08% 150
2025
Q3
$4.67M Buy
42,073
+2,053
+5% +$233K 0.06% 153
2025
Q2
$4.44M Buy
+40,020
New +$4.26M 0.08% 135
2024
Q4
Sell
-20,884
Closed -$1.75M 527
2024
Q3
$1.75M Buy
20,884
+3,779
+22% +$288K 0.04% 177
2024
Q2
$1.17M Buy
17,105
+4,683
+38% +$313K 0.03% 216
2024
Q1
$910K Buy
12,422
+65
+0.5% +$5K 0.02% 230
2023
Q4
$1M Sell
12,357
-92
-0.7% -$7.16K 0.03% 178
2023
Q3
$933K Buy
12,449
+444
+4% +$34.2K 0.03% 175
2023
Q2
$925K Buy
12,005
+3,090
+35% +$246K 0.03% 182
2023
Q1
$740K Buy
8,915
+3,000
+51% +$248K 0.03% 166
2022
Q4
$508K Sell
5,915
-810
-12% -$64.1K 0.02% 184
2022
Q3
$415K Buy
+6,725
New +$424K 0.02% 206
2021
Q4
Sell
-3,420
Closed -$239K 303
2021
Q3
$239K Buy
3,420
+283
+9% +$19.9K 0.02% 230
2021
Q2
$216K Sell
3,137
-63
-2% -$4.21K 0.02% 200
2021
Q1
$207K Sell
3,200
-353
-10% -$22.8K 0.02% 179
2020
Q4
$207K Buy
+3,553
New +$214K 0.03% 176
2020
Q3
Sell
-2,658
Closed -$204K 219
2020
Q2
$204K Buy
+2,658
New +$204K 0.04% 151
2018
Q2
Sell
-7,808
Closed -$348K 546
2018
Q1
$348K Buy
7,808
+2,265
+41% +$180K 0.06% 246
2017
Q4
$439K Buy
+5,543
New +$421K 0.06% 250

Other funds holding GILD

Summit Trail Advisors's GILD Position: Q1 2026 in Review

Summit Trail Advisors increased its Gilead Sciences (GILD) stake by 22% in Q1 2026, buying an estimated $1.11M and bringing the position to 43,831 shares worth $6.11M. The position accounts for 0.09% of the portfolio, ranked #127.

Summit Trail Advisors first reported a position in GILD in Q4 2017 and has held it in 20 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Summit Trail Advisors held 43,831 shares of Gilead Sciences worth $6.11M as of Q1 2026.
  • Summit Trail Advisors bought 7,917 Gilead Sciences shares in Q1 2026, an estimated $1.11M.
  • Gilead Sciences made up 0.09% of Summit Trail Advisors's portfolio in Q1 2026, its #127 holding.
  • Summit Trail Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 20 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.